{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:38:10Z","timestamp":1793151490272,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Juvenile psoriatic arthritis (JPsA) is a relatively rare condition in childhood as it represents approximately 5% of the whole Juvenile Idiopathic Arthritis (JIA) population. According to International League of Associations of Rheumatology (ILAR) classification, JPsA is defined by the association of arthritis and psoriasis or, in the absence of typical psoriatic lesions, with at least two of the following: dactylitis, nail pitting, onycholysis or family history of psoriasis in a first-degree relative. However, recent studies have shown that this classification system could conceal more homogeneous subgroups of patients differing by age of onset, clinical characteristics and prognosis. Little is known about genetic factors and pathogenetic mechanisms which distinguish JPsA from other JIA subtypes or from isolated psoriasis without joint involvement, especially in the pediatric population. Specific clinical trials testing the efficacy of biological agents are lacking for JPsA, while in recent years novel therapeutic agents are emerging in adults. In this review, we summarize the clinical features and the current evidence on pathogenesis and therapeutic options for JPsA in order to provide a comprehensive overview on the clinical management of this complex and overlapping entity in childhood.<\/jats:p>","DOI":"10.3389\/fped.2022.884727","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:44:48Z","timestamp":1654098288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["New Insights on Juvenile Psoriatic Arthritis"],"prefix":"10.3389","volume":"10","author":[{"given":"Francesco","family":"Brunello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Dell'Apa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Alfisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Calzamatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Folisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","first-page":"627","article-title":"Psoriatic arthritis","volume":"21","author":"Wright","year":"1971","journal-title":"Bull Rheum Dis."},{"key":"B2","first-page":"S40","article-title":"The conundrum of juvenile psoriatic arthritis","volume":"33","author":"Ravelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B3","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/art.23240","article-title":"Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis","volume":"59","author":"Stoll","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","article-title":"The ClASsification for Psoriatic ARthritis (CASPAR) criteria\u2013a retrospective feasibility, sensitivity, and specificity study","volume":"39","author":"Tillett","year":"2012","journal-title":"J Rheumatol."},{"key":"B8","first-page":"304","article-title":"Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria","volume":"28","author":"Congi","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3899\/jrheum.160717","article-title":"The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes","volume":"44","author":"Zisman","year":"2017","journal-title":"J Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17402520600877802","article-title":"Subpopulations within juvenile psoriatic arthritis: a review of the literature","volume":"13","author":"Stoll","year":"2006","journal-title":"Clin Dev Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1002\/art.22173","article-title":"Patients with juvenile psoriatic arthritis comprise two distinct populations","volume":"54","author":"Stoll","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol."},{"key":"B13","first-page":"582","article-title":"Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis","volume":"29","author":"Stoll","year":"2011","journal-title":"Clin Exp Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12969-017-0145-5","article-title":"Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study","volume":"15","author":"Ekelund","year":"2017","journal-title":"Pediatr Rheumatol Online J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-015-0003-2","article-title":"Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity","volume":"13","author":"Tuttle","year":"2015","journal-title":"Pediatr Rheumatol Online J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3899\/jrheum.080674","article-title":"Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they?","volume":"36","author":"Butbul","year":"2009","journal-title":"J Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0221-0363(06)74056-2","article-title":"[Ultrasound features of entesopathy in patients with psoriatic dactylitis]","volume":"87","author":"Lalande Champetier","year":"2006","journal-title":"J Radiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","article-title":"Childhood psoriasis: a clinical review of 1262 cases","volume":"18","author":"Morris","year":"2001","journal-title":"Pediatr Dermatol."},{"key":"B19","first-page":"1315","article-title":"Nail and distal interphalangeal joint in psoriatic arthritis","volume":"33","author":"Scarpa","year":"2006","journal-title":"J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/rheumatology\/kel214","article-title":"The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis\u2013a high-resolution MRI and histological study","volume":"46","author":"Tan","year":"2007","journal-title":"Rheumatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/ard.59.1.67","article-title":"Characterisation of uveitis in patients with psoriatic arthritis","volume":"59","author":"Paiva","year":"2000","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1468-3083.2009.03564.x","article-title":"Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies","volume":"24","author":"Prey","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/2475530318799072","article-title":"Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities","volume":"3","author":"Brandon","year":"2018","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/anr.1780320810","article-title":"Psoriatic arthritis in children","volume":"32","author":"Southwood","year":"1989","journal-title":"Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am."},{"key":"B27","first-page":"31","article-title":"Antinuclear antibodies in psoriatic arthritis and its subgroups","volume":"146","author":"Calzavara","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0950-3579(94)80021-9","article-title":"Juvenile psoriatic arthritis","volume":"8","author":"Ansell","year":"1994","journal-title":"Baillieres Clin Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J Cell Mol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/ard.42.2.142","article-title":"Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis","volume":"42","author":"Armstrong","year":"1983","journal-title":"Ann Rheum Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard.46.3.184","article-title":"Psoriatic arthritis: clinical subgroups and histocompatibility antigens","volume":"46","author":"McHugh","year":"1987","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/03009740410005953","article-title":"The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis","volume":"33","author":"Queiro-Silva","year":"2004","journal-title":"Scand J Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"ii37","DOI":"10.1136\/ard.2004.030775","article-title":"Genetic epidemiology of psoriasis and psoriatic arthritis","volume":"64","author":"Rahman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B36","first-page":"505","article-title":"HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis","volume":"30","author":"Queiro","year":"2003","journal-title":"J Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5114\/reum.2015.53133","article-title":"Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis","volume":"53","author":"Zuber","year":"2015","journal-title":"Reumatologia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/rheumatology\/41.10.1183","article-title":"Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients","volume":"41","author":"Thomson","year":"2002","journal-title":"Rheumatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B41","first-page":"1117","article-title":"Predominance of CD8+ T lymphocytes in psoriatic arthritis","volume":"26","author":"Costello","year":"1999","journal-title":"J Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","article-title":"Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis","volume":"73","author":"Leijten","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","article-title":"Review: genetics and the classification of arthritis in adults and children","volume":"70","author":"Nigrovic","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1546-0096-12-29","article-title":"Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry","volume":"12","author":"Sobel","year":"2014","journal-title":"Pediatr Rheumatol Online J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/acr.21947","article-title":"Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era","volume":"65","author":"Papadopoulou","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1136\/ard.2006.064717","article-title":"Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment","volume":"66","author":"van Rossum","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jpeds.2013.10.029","article-title":"Methotrexate: new uses for an old drug","volume":"164","author":"Hashkes","year":"2014","journal-title":"J Pediatr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/14712598.2013.840580","article-title":"Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis","volume":"13","author":"Berard","year":"2013","journal-title":"Expert Opin Biol Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3899\/jrheum.150430","article-title":"Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis","volume":"43","author":"Constantin","year":"2016","journal-title":"J Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-218456","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"102902","DOI":"10.1016\/j.autrev.2021.102902","article-title":"inhibitors and psoriatic arthritis: a systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e000990","DOI":"10.1136\/rmdopen-2019-000990","article-title":"Efficacy of ustekinumab in biologic-na\u00efve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2","volume":"5","author":"McInnes","year":"2019","journal-title":"RMD Open."},{"key":"B67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center","volume":"69","author":"Dayan","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1684\/ejd.2010.1177","article-title":"Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis","volume":"21","author":"Fotiadou","year":"2011","journal-title":"Eur J Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/ajd.12050","article-title":"Ustekinumab in the treatment of severe paediatric psoriasis","volume":"54","author":"Dixit","year":"2013","journal-title":"Australas J Dermatol."},{"key":"B70","first-page":"881","article-title":"Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.884727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:44:56Z","timestamp":1654098296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.884727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":75,"alternative-id":["10.3389\/fped.2022.884727"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.884727","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"884727"}}